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Single murine and human intestinal stem cells can be
expanded in culture over long time periods as genet-
ically and phenotypically stable epithelial organoids.
Increased cAMP levels induce rapid swelling of such
organoids by opening the cystic fibrosis transmem-
brane conductor receptor (CFTR). This response is
lost in organoids derived from cystic fibrosis (CF)
patients. Here we use the CRISPR/Cas9 genome
editing system to correct the CFTR locus by homolo-
gous recombination in cultured intestinal stem cells
of CF patients. The corrected allele is expressed
and fully functional as measured in clonally
expanded organoids. This study provides proof of
concept for gene correction by homologous recom-
bination in primary adult stem cells derived from
patients with a single-gene hereditary defect.We have previously described a culture system that allows
apparently indefinite in vitro expansion (for >1 year) of singlemurine Lgr5+ intestinal stem cells into a 3D small intestinal
epithelium (Sato et al., 2009). A crucial ingredient is the Wnt
agonistic R-spondin1, a ligand of Lgr5 (Carmon et al., 2011; de
Lau et al., 2011). Intestinal organoids or ‘‘miniguts’’ comprise
nearly intact physiology; self-renewing Lgr5+ stem cells and
the niche-supporting Paneth cells are located in a domain that
resembles the crypt, and enterocytes as well as goblet and
enteroendocrine cells move upward to build a villus-like domain
that lines the central lumen. Minor adaptation of this culture con-
dition allowed us to develop similar types of organoid cultures for
colon, stomach, liver, and pancreas using mouse and human
tissues (Barker et al., 2010; Huch et al., 2013b, 2013c; Jung
et al., 2011; Sato et al., 2011). Successful transplantation ofCellclonal organoids derived from single Lgr5+ stem cells into
damaged tissue has been demonstrated for mouse colon and
liver, making the organoid system a promising tool for adult
stem cell/gene therapy (Huch et al., 2013a; Yui et al., 2012).
Recently, several groups have demonstrated the use of the
CRISPR/Cas9 system for genome engineering in various species
(Chang et al., 2013; Cho et al., 2013; Cong et al., 2013; Friedland
et al., 2013; Hou et al., 2013; Hwang et al., 2013; Jinek et al.,
2013; Li et al., 2013; Mali et al., 2013; Nekrasov et al., 2013;
Shen et al., 2013; Wang et al., 2013; Xiao et al., 2013; Yu et al.,
2013). The system utilizes the type II prokaryotic CRISPR/Cas9
adaptive immune system and targets the Cas9 nuclease by a
20 nt guide sequence cloned upstream of a 50-NGG ‘‘proto-
spacer adjacent motif’’ (PAM) (Jinek et al., 2012). The induced
site-specific double-strand breaks are repaired either by nonho-
mologous end-joining (NHEJ) to yield indels (Barnes, 2001) or by
homologous recombination (HR) if homologous donor templates
are available (van den Bosch et al., 2002), thereby enhancing the
efficiency of HR-based gene targeting (Bibikova et al., 2003;
Porteus and Carroll, 2005; Thomas and Capecchi, 1987; Urnov
et al., 2005). The high efficiency and simple design principle of
the CRISPR/Cas9 system prompted us to evaluate its use for
gene manipulation of adult stem cells in Lgr5/R-spondin-based
organoid cultures.
We first optimized the CRISPR/Cas9 system by targeting the
murine APC locus in adult intestinal stem cells. The optimized
protocol involves culturing intestinal organoids in Wnt-condi-
tioned media, trypsinization to obtain a single cell suspension,
and Lipofectamine-mediated transfection with plasmids ex-
pressing Cas9 and sgRNAs targeting APC (Figures S1A and
S1B available online) (Schwank et al., 2013). Of note, only
Lgr5+ stem cells—and none of the other epithelial cell types—
will grow out in a clonal fashion into secondary organoids in
culture (Sato et al., 2009, 2011). As APC is a negative regulator
of the Wnt pathway, stem cells in which both APC alleles are in-
activated will grow out in the absence of the normally essentialStem Cell 13, 653–658, December 5, 2013 ª2013 Elsevier Inc. 653
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CRISPR/Cas9 in Intestinal Stem Cell OrganoidsWnt agonist R-spondin1. Two weeks after seeding transfected
single cells, multiple organoids grew out from the pool of cells
cotransfected with each of five different sgRNAs. In contrast to
budding wild-type organoids, selected APC mutant organoids
showed a cystic morphology (Figures 1A and 1A0), and
sequencing of isolated clones confirmed mutations in the
targeted APC locus (Figure 1B, Figure S1C). No organoids
grew in control transfections without the specific sgRNAs. Dou-
ble-targeting of the two negative Wnt regulators RNF43 and its
homolog Znrf3 (Hao et al., 2012; Koo et al., 2012) also resulted
in surviving organoids with frameshifts in both targeted loci (Fig-
ure S1D), demonstrating the possibility to efficiently generate
four-allele knockout organoids in a single transfection. We then
tested the CRISPR/Cas9 system on human adult intestinal
stem cells by targeting the APC locus. As human intestinal
stem cells in culture require additional Wnt for self-renewal and
expansion (Jung et al., 2011; Sato et al., 2011), transfected
stem cells were seeded in medium lacking both Wnt and
R-spondin. Organoids only grew out from the pool of cells
cotransfected with the specific sgRNA, and selected clones
showed a cysticmorphology (Figure 1C0). Sequencing confirmed
mutations in the targeted region (Figure 1D), demonstrating the
potential of theCRISPR/Cas9 system for genome editing of adult
human stem cells in primary intestinal organoids.
To investigate the possibility of gene correction in adult stem
cells using CRISPR/Cas9, we focused on the cystic fibrosis
transmembrane conductor receptor (CFTR) in primary cultured
small intestinal (SI) and large intestinal (LI) stem cells. CFTR
encodes an anion channel essential for fluid and electrolyte
homeostasis of epithelia. Mutations in this receptor cause cystic
fibrosis (CF) (Kerem et al., 1989; Riordan et al., 1989; Rommens
et al., 1989), a disease that leads to the accumulation of viscous
mucus in the pulmonary and gastrointestinal tract and to a cur-
rent median life expectancy of approximately 40 years (Ratjen
and Do¨ring, 2003). We established SI and LI organoids from
two different pediatric CF patients. Both patients were homozy-
gous for the most common CFTRmutation, a deletion of phenyl-
alanine at position 508 (CFTR F508 del) in exon 11, which causesFigure 1. CRISPR/Cas9-Mediated Genome Editing in Adult Stem Cells
(A–D) Generation of indels in themouse and humanAPC locus. (A) Wild-typemous
intestinal organoids generated with the CRISP/Cas9 system and selected in me
budding structures (wild-type) to cystic structures (APC). (B) Schematic of the targ
selected clones. Regions of the sgRNA complementary to the protospacer (yello
human intestinal organoids in complete growth medium, and (C0) APC mutant hu
Schematic of the targeted region of the human APC locus, and sequences of fiv
(E–J) Correction of the humanCFTR F508del allele by induced homologous recom
double-strand breaks in theCFTR locus, and a template for homology directed rep
strokes illustrate introns. Red scissors show cleavage sites of sgRNA1 and sgR
cassette. A 2 bp silent mutation is introduced downstream of the CTT F508del cor
primer pairs. (F) Schematic representation of base pairing of the targeting locus
corresponding sequences in the targeting vector. Nonmatching bases are shown
of the selection cassette, respectively. (G) PCR analysis showing insertion of th
primers-pairs are illustrated in (E). SI_c1: clone derived from SI organoids of patien
of patient 1 corrected by cleavage with sgRNA2. SI_c3: same as SI_c2, but integr
derived from LI organoids of patient 2, corrected by cleavage with sgRNA1. LI_
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forward primer is located in exon 10. (I and J) PCR amplification products of the co
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mutant allele (data not shown).
See also Figure S1, Table S1, and Table S2.
Cellmisfolding, endoplasmic reticulum retention, and early degrada-
tion of the CFTRprotein (Cheng et al., 1990). To first demonstrate
the loss of the CFTR function, we performed the previously
established forskolin-induced swelling assay. Forskolin acti-
vates CFTR by raising the amount of intracellular cyclic AMP,
leading to fluid secretion into the lumen and swelling of organo-
ids (Dekkers et al., 2013). Unlike wild-type organoids, the CFTR
F508 del patient organoids did not expand their surface area
upon forskolin treatment (Figures 2A, 2C, and 2D), confirming
loss of function of CFTR as published previously.
We then transfected the patient organoids independently with
two different sgRNAs targeting either CFTR exon 11 or intron 11,
together with a donor plasmid encoding wild-type CFTR
sequences (Figure 1E). Downstream of the corrected F508 del
mutation, we introduced a silent mutation into the donor
sequence enabling allele-specific PCR testing. Within the
intronic sequence, we incorporated a puromycin resistance
cassette (Figure 1E). The sgRNAs were designed to cut the
genomic CFTR sequence, but not the homologous sequence
within the targeting vector (Figure 1F). After transfection single
cells were plated, and organoids derived from puromycin-resis-
tant individual stem cells were selected and tested for site-
specific integration of the donor plasmid by PCR with primers
outside of the 50 and 30 homology arms and within the puromycin
selection cassette (Figure 1E). For both patients, we retrieved
several organoid clones with each of the two sgRNAs (Table
S1; selected clones are shown in Figure 1G). We confirmed
site-specific knockin events and correction of the F508 del allele
by sequencing the recombined allele (Figure 1I). Note that
sequencing the second allele revealed heterozygous CFTR
repair in the majority of clones (Table S1). Transfection with
sgRNA2, which induces a double-strand break 203 base pairs
(bp) downstream of the F508 del mutation also generated a clone
with an anecdotal knockin event where the recombination
appeared downstream of the mutation and repair was not
achieved (SI_c3 in Figure 1G). To validate expression of the
corrected allele, we performed RT-PCR using a forward primer
in exon 10 and an allele-specific reverse primer that bindse intestinal organoids in complete growthmedium, and (A0)APCmutant mouse
dium without R-spondin. Note that organoids change their morphology from
eted region of the mouseAPC locus, and sequences of five mutant alleles from
w) are shown in blue. Red arrowheads indicate cleavage sites. (C) Wild-type
man intestinal organoids selected in medium without Wnt and R-spondin. (D)
e mutant alleles from selected clones.
bination. (E) Strategy of the genomemodification usingCRISPR/Cas9 to induce
air. Top line, structure of theCFTR gene. Black boxes illustrate exons, and thin
NA2, and white box in the targeting vector indicates the puromycin selection
rection and allows allele-specific PCR testing. Pp1, Pp2, and Pp3 illustrate PCR
with sgRNA1 (upper panel) and sgRNA2 (lower panel). Top lines illustrate the
in orange and are based on the F508del correction (CTT addition) and insertion
e targeting vector by homologous recombination. Positions of Pp1 and Pp2
t 1 corrected by cleavage with sgRNA1. SI_c2: clone derived from SI organoids
ation of the selection cassette did not result in F508 del correction. LI_c1: clone
c2: clone derived from LI organoids of patient 2, corrected by cleavage with
orrected allele Pp3(TC) and the uncorrected allele Pp3(CA), respectively. Pp3
rrected alleles (from G and H) were sequenced. This revealed correction of the
wn here are heterozygous for the corrected allele and retained one copy of the
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Figure 2. Functional Analysis of the Restored CFTR Function in Corrected Organoids
(A and B) Confocal images of calcein-green-labeled and forskolin-stimulated SI organoids (A) without and (B) in the presence of a chemical CFTR inhibitor. SI_c1,
SI_c2: clones derived from SI organoids corrected by cleavage with sgRNA1 and sgRNA2, respectively. F508 del: uncorrected control organoids of the
corresponding patient. t = 0 min, t = 60 min indicate time points after forskolin induction.
(C and D) Quantification of organoid swelling of corrected SI organoid clones (C) and LI organoid clones (D). The total organoid surface area is normalized to t0min
and measured in three independent wells. Error bars indicate the standard error of the mean (SEM). inh, chemical CFTR inhibitor.
(E and F) Forskolin-induced swelling expressed as the absolute area under the curve calculated from (C) and (D), respectively (baseline = 100%, t = 60 min). Error
bars indicate SEM.
(G) Schematic illustration of the gene correction protocol. Stem cells are labeled in green. Note that after transfection only stem cells that integrated the selection
cassette can grow out and form new organoids.
See also Movie S1.
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CRISPR/Cas9 in Intestinal Stem Cell Organoidsexclusively to the introduced silent mutations in exon 11. Expres-
sion of the repaired allele was absent in uncorrected control
organoids and detected in all transgenic clones (Figures 1H
and 1J). RT-PCR with a reverse primer specific for the uncorrec-
ted allele confirms heterozygousity of the knockin events.
It has been reported that sgRNAs can potentially tolerate
mismatches in the 20 bp protospacer target sequence, which
can lead to the generation of undesirable ‘‘off-target’’ indels
(Hsu et al., 2013; Mali et al., 2013; Pattanayak et al., 2013). To
assess off-target effects of the CRISPR/Cas9 system in our adult656 Cell Stem Cell 13, 653–658, December 5, 2013 ª2013 Elsevier Inprimary stem cell system, we computationally identified possible
off-target sites for each of the two sgRNAs (sequences with one
to three mismatches to the protospacer followed by the NGG-
PAM motif). We identified 29 potential off-target sites for
sgRNA1, of which 25 were sequenced and analyzed in an
individual clone. Only one site contained a 4 bp insertion in the
protospacer sequence (Table S2). Notably, the mutation was
heterozygous and located within an intron, making phenotypic
consequences highly unlikely. For sgRNA2, we identified and
sequenced 17 off-target sites in one clone, and no mutationsc.
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CRISPR/Cas9 in Intestinal Stem Cell Organoidswere found (Table S2). Also, when protospacer-homology re-
gions with 4 mismatches (10 sites for sgRNA1 and 8 sites for
sgRNA2) were analyzed, we did not find any indels (Table S2),
confirming previous studies that suggest off-target effects to
be limited to sites with only one to three mismatches (Mali
et al., 2013). Our results therefore demonstrated high specificity
of the CRISPR/Cas9 system in adult stem cells.
To assess whether the CFTR function in corrected organoids
was restored, we performed the forskolin assay with transgenic
lines. By live-cell microscopy, we observed rapid expansion of
the organoid surface area in the corrected organoids, whereas
swelling was absent in untransfected control organoids
(Figure 2A, Movie S1). Quantification of swelling by automated
image analysis demonstrated a relative increase of the total
organoid surface area to 177% (±1.4 SEM) and 167% (±3.8
SEM) for two corrected SI organoid clones (Figures 2C and
2E), and to 187% (±3 SEM) and 180% (±1.5 SEM) for two cor-
rected LI organoid clones (Figures 2D and 2F). These numbers
are comparable to forskolin-induced surface area increase of
wild-type organoids and exceed CFTR rescue capacities
obtained with chemical correctors (Dekkers et al., 2013). Un-
transfected F508 del organoids increased only marginally in sur-
face area (Figures 2C–2F), which is consistent with very limited
residual CFTR function of the F508 del allele (Dekkers et al.,
2013). We next tested whether the forskolin-induced swelling
of the corrected organoids was sensitive to chemical inhibition
of CFTR by CFTRinh-172 (Thiagarajah et al., 2004). Indeed, for-
skolin-induced swelling was fully abolished in presence of the
inhibitor (Figures 2C–2F, Movie S1). Together, these data
demonstrated that the corrected F508 del allele was fully func-
tional and was able to rescue the CFTR phenotype in organoids.
In summary, we have isolated and expanded adult intestinal
stem cells from two CF patients, corrected the mutant F508
del allele using the CRISPR/Cas9 mediated homologous recom-
bination, and demonstrated functionality of the corrected allele
in the organoid system (Figure 2G). Together with previous
studies, in which in vitro expanded organoids were successfully
transplanted into colons of mice (Yui et al., 2012), this work pro-
vides a potential strategy for future gene therapy in patients.
Although given its multiorgan involvement CF does not appear
to be a prime candidate for clinical application of adult stem
cell gene therapy, this approachmay present a safe complement
to induced-pluripotent-stem-cell-based approaches, and in the
future it could be applied to different single-gene hereditary
defects. The advantage of combining HR-based gene correction
strategies with organoid culture technology rests in the possibil-
ity of clonal expansion of single adult patient stem cells and the
selection of recombinant clonal organoid cultures harboring the
desired, exact genetic change.
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